Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Somnomed Limited ( (AU:SOM) ) has provided an update.
SomnoMed Limited announced a change in the director’s interest, with Amrita Singh Blickstead acquiring 600,000 zero exercise price options, increasing her total to 1,925,000 options. Additionally, the company plans to issue 1,000,000 options under the SomnoMed Employee Share Option Plan, contingent on shareholder approval, with a two-year expiry and a $0.65 exercise price, reflecting strategic incentives for key personnel.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited operates in the healthcare industry, specializing in the development and distribution of oral appliances for the treatment of sleep-related disorders, particularly obstructive sleep apnea. The company focuses on providing innovative solutions to improve sleep health and quality of life for patients globally.
Average Trading Volume: 67,993
Technical Sentiment Signal: Hold
Current Market Cap: A$141.6M
See more data about SOM stock on TipRanks’ Stock Analysis page.